MDT

95.62

+0.66%↑

VEEV

283

-3.27%↓

A

141.9

+0.66%↑

HQY

91.19

+0.35%↑

TLRY

1.55

+1.31%↑

MDT

95.62

+0.66%↑

VEEV

283

-3.27%↓

A

141.9

+0.66%↑

HQY

91.19

+0.35%↑

TLRY

1.55

+1.31%↑

MDT

95.62

+0.66%↑

VEEV

283

-3.27%↓

A

141.9

+0.66%↑

HQY

91.19

+0.35%↑

TLRY

1.55

+1.31%↑

MDT

95.62

+0.66%↑

VEEV

283

-3.27%↓

A

141.9

+0.66%↑

HQY

91.19

+0.35%↑

TLRY

1.55

+1.31%↑

MDT

95.62

+0.66%↑

VEEV

283

-3.27%↓

A

141.9

+0.66%↑

HQY

91.19

+0.35%↑

TLRY

1.55

+1.31%↑

Search

Quidel Corp

Geschlossen

28.12 -1.26

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

27.79

Max

28.39

Schlüsselkennzahlen

By Trading Economics

Angestellte

6,600

Empfehlungen

By TipRanks

Empfehlungen

Buy

12-Monats-Prognose

+38.99% upside

Dividenden

By Dow Jones

Nächstes Ergebnis

6. Nov. 2025

Marktstatistiken

By TradingEconomics

Marktkapitalisierung

127M

1.5B

Vorheriger Eröffnungskurs

29.38

Vorheriger Schlusskurs

28.12

Quidel Corp Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

17. Okt. 2025, 18:13 UTC

Wichtige Markttreiber

Revolution Medicines Rises as FDA Grants Priority Designation for Cancer Treatment

17. Okt. 2025, 17:05 UTC

Wichtige Markttreiber

Artiva Biotherapeutics Shares Jump After Treatment Gets Fast Tracked

17. Okt. 2025, 15:03 UTC

Wichtige Markttreiber

Obook Shares Sink Following Public Debut

17. Okt. 2025, 14:41 UTC

Wichtige Markttreiber

Disc Medicine Shares Surge After FDA Grants Priority Voucher for EPP Drug

17. Okt. 2025, 23:25 UTC

Akquisitionen, Fusionen, Übernahmen

New Zealand's 'Golden Visa' Targets the Affluent in Search of Plan B -- Barrons.com

17. Okt. 2025, 22:15 UTC

Market Talk

Ulta's CFO Appointment Seen Supporting Growth -- Market Talk

17. Okt. 2025, 21:15 UTC

Market Talk

Greece Expected to Post Overall Budgetary Surplus This Year -- Market Talk

17. Okt. 2025, 21:07 UTC

Market Talk

Oracle Stock Expected to Take a Breather as Capex Climbs -- Market Talk

17. Okt. 2025, 21:07 UTC

Market Talk

Global Equities Roundup: Market Talk

17. Okt. 2025, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

17. Okt. 2025, 20:34 UTC

Market Talk

Deere Is Reaching the End of Its Downcycle -- Market Talk

17. Okt. 2025, 20:27 UTC

Market Talk

Soft Growth Ahead in Canada But Not Far Off From Potential GDP, Macklem Says -- Market Talk

17. Okt. 2025, 19:46 UTC

Market Talk

U.S. Natural Gas Futures Snap Losing Streak -- Market Talk

17. Okt. 2025, 19:45 UTC

Market Talk

Oil Futures Stabilize, But End Week With A Loss -- Market Talk

17. Okt. 2025, 18:45 UTC

Market Talk

Treasury Yields, Dollar Try to Reclaim Some Ground -- Market Talk

17. Okt. 2025, 17:51 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

17. Okt. 2025, 17:51 UTC

Market Talk

Euro Still a Long Way From Supplanting Dollar, Former ECB Rate Setter Says -- Market Talk

17. Okt. 2025, 17:44 UTC

Market Talk

EQT Seen With Long-Term Growth Opportunities -- Market Talk

17. Okt. 2025, 17:35 UTC

Market Talk

U.S. Oil Rig Count Unchanged at 418 -- Market Talk

17. Okt. 2025, 16:20 UTC

Market Talk
Ergebnisse

Tech, Media & Telecom Roundup: Market Talk

17. Okt. 2025, 16:20 UTC

Market Talk

Basic Materials Roundup: Market Talk

17. Okt. 2025, 16:14 UTC

Market Talk

Home Depot Will Gain From Pick Up in Home Improvement Activity -- Market Talk

17. Okt. 2025, 16:04 UTC

Market Talk

Home Improvement Demand Is Starting to Pick Up -- Market Talk

17. Okt. 2025, 15:58 UTC

Market Talk

Amazon's Project Rainier Will Begin to Stem Its AI Share Losses -- Market Talk

17. Okt. 2025, 15:56 UTC

Ergebnisse

These Stocks Are Moving the Most Today: Zions Bancorp, Jefferies, Amex, Oracle, Novo Nordisk, Lilly, State Street, CSX, and More -- Barrons.com

17. Okt. 2025, 15:43 UTC

Market Talk

Global Equities Roundup: Market Talk

17. Okt. 2025, 15:43 UTC

Market Talk

Amazon's Earnings Are About Sentiment of Consumers, Not Investors -- Market Talk

17. Okt. 2025, 14:58 UTC

Market Talk

Small-Business Trepidation in Canada Points to Economic Decline -- Market Talk

17. Okt. 2025, 14:41 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

17. Okt. 2025, 14:35 UTC

Market Talk
Ergebnisse

American Express's Delayed Card Fee Hike Worries Some Investors -- Market Talk

Peer-Vergleich

Kursveränderung

Quidel Corp Prognose

Kursziel

By TipRanks

38.99% Vorteil

12-Monats-Prognose

Durchschnitt 39.5 USD  38.99%

Hoch 62 USD

Tief 26 USD

Basierend auf 8 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Quidel Corp – Dist angeboten haben.

Rating-Konsens

By TipRanks

Buy

8 ratings

4

Buy

3

Halten

1

Sell

Finanzen

$

Über Quidel Corp

QuidelOrtho Corporation provides diagnostic testing solutions. The company operates through Labs, Transfusion Medicine, Point-of-Care, and Molecular Diagnostics business units. The Labs business unit provides clinical chemistry laboratory instruments and tests that measure target chemicals in bodily fluids for the evaluation of health and the clinical management of patients; immunoassay laboratory instruments and tests, which measure proteins as they act as antigens in the spread of disease, antibodies in the immune response spurred by disease, or markers of proper organ function and health; testing products to detect and monitor disease progression across a spectrum of therapeutic areas; and specialized diagnostic solutions. The Transfusion Medicine business unit offers immunohematology instruments and tests used for blood typing to ensure patient-donor compatibility in blood transfusions; and donor screening instruments and tests used for blood and plasma screening for infectious diseases. The Point-of-Care business unit provides instruments and tests to provide rapid results across a continuum of point-of-care settings. The Molecular Diagnostics business unit offers polymerase chain reaction thermocyclers; amplification systems; and sample-to-result molecular instruments and tests for syndromic infectious disease diagnostics. The company sells its products directly to end users through a direct sales force; and through a network of distributors for professional use in physician offices, hospitals, clinical laboratories, reference laboratories, urgent care clinics, universities, retail clinics, pharmacies, wellness screening centers, blood banks, and donor centers, as well as for individual, non-professional, and over-the-counter use. It operates in North America, Europe, the Middle East, Africa, China, and internationally. The company was incorporated in 1979 and is headquartered in San Diego, California.
help-icon Live chat